Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MALTA, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- GlobalFoundries (Nasdaq: GFS) (GF), a leading American semiconductor manufacturer, today announced that it has filed multiple lawsuits in the U.S....
-
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
-
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
-
Agomab today announced that the USPTO granted a patent covering the composition of matter of AGMB-447.
-
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH,...
-
BURLINGAME, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Roadzen Inc. (Nasdaq: RDZN), a global leader in AI at the convergence of insurance and mobility, today announced that drivebuddyAI, its driver...
-
Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
-
ENGLEWOOD, Colo., March 24, 2026 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO), a leader in sustainable fuels and carbon management, today highlights the strategic value of its intellectual property...
-
Nasdaq Private Market receives U.S. patent for settlement engine for private company securities, a first for the private market industry
-
Key combination for the treatment of first-line AMLRecent data from an ongoing study in first-line AML showed a 100% overall response rate (ORR) with iadademstat in combination with venetoclax and...